[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-health":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,79,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100624843","group-postpartum-and-well-child-care-for-maternal-and-infant-health-100624843",false,"NCT07414901","Group Postpartum and Well-Child Care for Maternal and Infant Health","Evaluating the Effectiveness of an Integrated Group Postpartum and Well-child Care Model on Maternal and Child Health Outcomes","Inclusion Criteria:\n\nAims 1\\&2:\n\n* Women presenting for their 1-week postnatal care visit with their infant at a study site clinic.\n* Over age 15.\n* One infant is less than 4 weeks old.\n* Able to speak and understand Chichewa.\n* Adolescents 15-17 must bring parent\u002Fguardian for consent\u002Fassent. Infants included as part of mother-infant dyad.\n\nAim 3:\n\n* Midwife or HSA serving as group care co-facilitator or key stakeholders in MoH\u002FZomba District\u002Fclinical administration\n* Able to speak Chichewa and\u002For English.\n\nExclusion Criteria:\n\nAim 1\\&2\n\n* Under age 15.\n* Serious physical or mental illness or marked cognitive impairment preventing informed consent.\n* Inability to participate in full intervention\n* Multiple infants (e.g. twins, triplets)\n\nAim 3\n\n-Serious physical or mental illness or marked cognitive impairment preventing informed consent.",true,"ALL","1 Week","75 Years",{"count":21,"type":22},1125,"ESTIMATED","INTERVENTIONAL",[25],"NA","The proposed study will evaluate the effectiveness of an integrated group postpartum and well-child care model, compared to individual (usual) postnatal and well-child care, on maternal and child health outcomes. Results will provide clinical evidence for improved maternal and infant health care in the first year postpartum. The study will inform and provide lessons learned to advance maternal and infant health service delivery models in low resource settings.",[28,29],"Postpartum Health","Infant Health","RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-07","ACTUAL",{"date":36,"type":34},"2026-03-30",{"date":38,"type":22},"2030-01-30",{"name":40,"class":41},"Johns Hopkins University","OTHER",16,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100578015","stress-reactivity-and-mother-infant-cardiovascular-disease-risk-100578015","NCT06805799","Stress Reactivity and Mother-Infant Cardiovascular Disease Risk","Maternal-Infant Stress Reactivity as an Intergenerational Pathway to Cardiovascular Disease Risk","Inclusion Criteria:\n\n* For the parent RCT study: Inclusion criteria: singleton pregnancy, English speaking, \\>18 years old, \\\u003C20 weeks' gestation at enrollment, normotensive at enrollment, and criteria consistent with 'moderate' to 'high' risk for preeclampsia based on American College of Obstetrician and Gynecologist guidelines. For the current research study: Participants will be (n=40) individuals from the parent RCT who have consented to be contacted for future research in the parent study and are not pregnant during the mentored research study procedures.\n\nExclusion Criteria:\n\nFor the parent RCT study: Exclusion criteria: multiple gestations; chronic hypertension; active suicidality or psychosis; ongoing mind-body practice (e.g., yoga, meditation, mindfulness \\> once a week).\n\n\\-","FEMALE","6 Months",{"count":53,"type":22},40,[25],"Prenatal Mindfulness training (MT) shows promise as a preventive intervention against hypertensive disorders of pregnancy (HDP) and may reduce risk for offspring cardiovascular disease (CVD). One proposed mechanism of MT to reduced CVD risk is improved self-regulation following stress. Perhaps the most crucial contributor to the development of self-regulation in the first year is the psychophysiological coregulatory relationship between mother and infant. However, this self-and co-regulation among women exposed to prenatal MT has not been studied and has yet to be examined in relation to CVD risk. The goal of this proposed project is to evaluate maternal-infant physiological reactivity to and recovery from stress at 6 months postpartum following prenatal MT, and to examine the relationship between these maternal infant stress responses and maternal-infant CVD risk at 12 months postpartum.\n\nUsing a lab-based stress paradigm and well-validated biomarkers of mother and infant CVD risk, the investigators will assess respiratory sinus arrhythmia and heart rate at 6 months postpartum for 40 mother-infant dyads who have completed either prenatal MT or a usual care arm of an RCT examining MT for women at risk for HDP. The investigators will compare maternal, infant, and dyadic stress responses by treatment arm. Then, cardiac stress responses will be examined as predictors of maternal and infant biomarkers of CVD risk at 12 months postpartum.",[57,29,58,59,60,61,62,63],"Maternal Health","Hypertension","Behavioral Medicine","Mindfulness","Psychophysiology","Cardiovascular Diseases","Cardiovascular Diseases Risk",[60,61,65,66,67,58],"Coregulation","Maternal-infant Coregulation","Cardiovascular Disease Risk","NOT_YET_RECRUITING","2026-03-31",{"date":71,"type":34},"2026-04-01",{"date":73,"type":22},"2026-04-15",{"date":75,"type":22},"2026-07-31",{"name":77,"class":41},"Lifespan",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100505978","effect-of-partially-hydrolyzed-whey-based-infant-formulas-on-growth-and-tolerability-in-healthy-term-infants-100505978","NCT05868408","Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants","Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants: a Double-blind, Randomized, Controlled, Multi-arm Trial","Inclusion Criteria:\n\n1. Written informed consent has been obtained from at least one parent (or other legally acceptable representative \\[LAR\\]), if applicable)\n2. Infant gestational age ≥37 completed weeks\n3. Infant birth weight of ≥2.5 kg and ≤4.5 kg\n4. Singleton birth\n5. Infant postnatal age ≤28 days (date of birth = day 0)\n6. Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk\n7. Infant's parent(s)\u002FLAR is of legal age of majority, must understand the informed consent form and other relevant study documents, and is willing and able to fulfill the requirements of the study protocol\n\nExclusion Criteria:\n\n1. Chronic infectious, metabolic, genetic illness or other disease, including any condition that impacts feeding or growth\n2. Major congenital or chromosomal abnormality known to affect growth (e.g., congenital heart disease, cystic fibrosis)\n3. Maternal medical conditions known to affect infant growth (e.g., untreated preeclampsia or gestational diabetes)\n4. Infants with special dietary needs other than standard infant formula\n5. Infants with known (or symptoms suggestive of) cow's milk protein intolerance\u002Fallergy, or lactose intolerance or severe food allergies that impact diet\n6. Child has other medical or psychiatric condition that, in the judgement of the investigator, would make the child inappropriate for entry into the study\n7. Currently participating or having participated in another interventional clinical trial prior to enrollment","0 Days","28 Days",{"count":89,"type":22},234,[25],"This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.",[93,94,29,95,96],"Infant Nutritional Physiological Phenomena","Infant Formula","Infant Development","Growth and Development","2025-12-18",{"date":99,"type":34},"2025-12-19",{"date":101,"type":34},"2023-08-17",{"date":103,"type":22},"2028-06",{"name":105,"class":106},"Société des Produits Nestlé (SPN)","INDUSTRY",3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":16,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":146,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":78},"100469557","generation-victoria-cohort-2020s-a-statewide-longitudinal-cohort-study-of-victorian-children-and-their-parents-100469557","NCT05394363","Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents","Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents","GenV","Inclusion Criteria (Children):\n\n* Birth date between 4th October 2021 and 3rd October 2023\n* Live at the time of recruitment\n* Residing in Victoria at the time of recruitment\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the child's behalf, who provides a signed and dated informed consent form (e.g. a parent\u002Fguardian)\n\nInclusion Criteria (Adults):\n\n* Be a parent or guardian of a child who meets the eligibility criteria above\n* Provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion criteria:\n\n* Children who are deceased at the time of recruitment (i.e. still born or died after birth) and their parents\u002Fguardians\n* Families unable to provide informed consent in any of the languages available","1 Day",{"count":118,"type":22},150000,"OBSERVATIONAL","Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.\n\nThe GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.",[122,123,29,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145],"Mental Health","Child Wellbeing","Child Health","Reproductive Health","Healthy Aging","Health Equity","Quality of Life","Social Determinants of Health","Environmental Exposure","Genetics","Cognition","Learning","Child Development","Congenital Abnormalities","Disability","Injuries","Communicable Diseases","Noncommunicable Diseases","Physical Fitness","Diet","Obesity","Allergy and Immunology","Inflammation","Intergenerational Relations",[147,114,148,149,150,124,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,127,167,168,169,170,171,172,173,129,174,175],"Generation Victoria","Cohort Studies","Data Collection","Data Linkage","Midlife Health","Children","Infants","Family","Parents","Mothers","Fathers","Life course perspective","Population Health","Longitudinal Studies","Genetics, population","Demography","Epidemiology","Health Disparity","Minority Health","Vulnerable Populations","Clinical Trial","Randomized Controlled Trial","Pragmatic Clinical Trial","Health Services Research","Economic Models","Value of Life","Geographic Information Systems","Climate Change","Built Environment","2025-07-30",{"date":178,"type":34},"2025-08-03",{"date":180,"type":34},"2021-10-04",{"date":182,"type":22},"2033-10",{"name":184,"class":41},"Murdoch Childrens Research Institute"]